Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) plus linagliptin (lina) vs ramucirumab (ram) plus paclitaxel (pac) in MORPHEUS-gastric cancer

被引：0
|
作者：
Lee, J. [1 ]
Ajani, J. A. [2 ]
Chung, H. C. [3 ]
Kang, Y-K. [4 ]
Iqbal, S. [5 ]
Allen, S. [6 ]
Al-Sakaff, N. [7 ]
Decalf, J. [8 ]
Li, S. [9 ]
Pintoffl, J. [7 ]
Sayyed, P. [7 ]
Bang, Y-J. [10 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hem Oncol, Seoul, South Korea
[2] MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA
[3] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Med Oncol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[5] USC Norris Comprehens Canc Ctr, Dept Oncol, Los Angeles, CA USA
[6] Genentech Inc, Oncol Biomarker Dev, South San Francisco, CA USA
[7] F Hoffmann La Roche Ltd, Prod Dev Oncol, Basel, Switzerland
[8] Genentech Inc, Dept Canc Immunol, South San Francisco, CA USA
[9] Biostat Roche China Holding Ltd, Shanghai, Peoples R China
[10] Seoul Natl Univ, Internal Med, Coll Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1491
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1382P
引用
收藏
页码：S1047 / S1047
页数：1
相关论文
共 50 条
  • [31] Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer
    Horita, Y.
    Nishino, M.
    Sugimoto, S.
    Kida, A.
    Mizukami, A.
    Yano, M.
    Arihara, F.
    Matsuda, K.
    Matsuda, M.
    Sakai, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer
    Horita, Yosuke
    Nishino, Michiko
    Sugimoto, Saiho
    Kida, Akihiko
    Mizukami, Atsuyoshi
    Yano, Masaaki
    Arihara, Fumitaka
    Matsuda, Koichiro
    Matsuda, Mitsuru
    Sakai, Akito
    ANTI-CANCER DRUGS, 2019, 30 (01) : 98 - 104
  • [33] Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial
    Zhang, Changgong
    Chen, Jianhua
    Wu, Huijuan
    Wang, Jun
    Gao, Liying
    Zhao, Jun
    Sun, Yan
    Jia, Zhongyao
    Mu, Xinlin
    Bai, Chunmei
    Wang, Rui
    Wu, Kailiang
    Liu, Qiang
    Shi, Yuankai
    CANCER PATHOGENESIS AND THERAPY, 2024, 2 (04): : 268 - 275
  • [34] Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis
    Rha, Sun Young
    Kim, Chang Gon
    Jung, Minkyu
    Kim, Hyo Song
    Lee, Choong-kun
    Jeung, Hei-Cheul
    Koo, Dong-Hoe
    Bae, Woo Kyun
    Zang, Dae Young
    Kim, Hyunki
    Chung, Hyun Cheol Cheol
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [35] Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial
    Huh, Gunn
    Lee, Hee Seung
    Choi, Jin Ho
    Lee, Sang Hyub
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Bang, Seungmin
    Lee, Eaum Seok
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [36] Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
    Hu, Zhihuang
    Sun, Si
    Zhao, Xinmin
    Yu, Hui
    Wu, Xianghua
    Wang, Jialei
    Chang, Jianhua
    Wang, Huijie
    ONCOLOGIST, 2022, 27 (04): : 253 - +
  • [37] Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC).
    Muro, Kei
    Yoshikawa, Takaki
    Shitara, Kohei
    Oh, Do-Youn
    Kang, Yoon-Koo
    Chung, Hyun Cheol
    Kudo, Toshihiro
    Chin, Keisho
    Kadowaki, Shigenori
    Hamamoto, Yasuo
    Hironaka, Shuichi
    Yoshida, Kazuhiro
    Yen, Chia-Jui
    Omuro, Yasushi
    Bai, Li-Yuan
    Maeda, Kaijiro
    Ozeki, Akichika
    Yoshikawa, Reigetsu
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Comparing effectiveness and safety of paclitaxel plus raltitrexed vs. paclitaxel alone in second-line palliative chemotherapy for metastatic gastric adenocarcinoma: A randomized phase II clinical trial
    Zhao, Xiaoying
    Chen, Zhiyu
    Zhang, Xiaowei
    Zhu, Xiaodong
    Zhang, Wen
    Qiu, Lixin
    Wang, Chenchen
    Huang, Mingzhu
    Zhang, Zhe
    Li, Wenhua
    Yang, Lei
    Guo, Weijian
    CANCER BIOLOGY & MEDICINE, 2023, 20 (09) : 682 - 688
  • [39] Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study
    Wei, Qing
    Xu, Xiaoqing
    Li, Jingjing
    Wang, Chang
    Chen, Weijun
    Xie, Yanru
    Luo, Cong
    Chen, Lei
    Chu, Jiadong
    Wu, Wei
    Han, Zhe
    Yang, Yanlian
    Hu, Zhiyuan
    Xu, Qi
    Ying, Jieer
    ONCOLOGIST, 2024, 29 (04): : e364 - e578
  • [40] Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies
    Shah, Manish A.
    Udrea, Anghel Adrian
    Bondarenko, Igor
    Mansoor, Was
    Sanchez, Raquel Guardeno
    Sarosiek, Tomasz
    Bozzarelli, Silvia
    Schenker, Michael
    Gomez-Martin, Carlos
    Morgan, Carys
    oezgueroglu, Mustafa
    Pikiel, Joanna
    Kalofonos, Haralabos P.
    Wojcik, Elzbieta
    Buchler, Tomas
    Swinson, Daniel
    Cicin, Irfan
    Joseph, Mano
    Vynnychenko, Ihor
    Luft, Alexander Valerievich
    Enzinger, Peter C.
    Salek, Tomas
    Papandreou, Christos
    Tournigand, Christophe
    Maiello, Evaristo
    Wei, Ran
    Ferry, David
    Gao, Ling
    Oliveira, Joana M.
    Ajani, Jaffer A.
    CANCERS, 2022, 14 (05)
12345